Fixed-Dose Combinations for HIV/AIDS, Tuberculosis, and Malaria - Report of a Meeting Held 16-18 December 2003 Geneva: Effect of fixed-dose combination (FDC) medications on adherence and treatment outcomes: References

Fixed-Dose Combinations for HIV/AIDS, Tuberculosis, and Malaria - Report of a Meeting Held 16-18 December 2003 Geneva
(2003; 199 pages)

Table of Contents

	Summary: Observations and some ways forward
		A. Overall observations
		B. Experiences with fixed-dose combinations
		C. Public health priorities
		D. IP and legal options
		E. Pharmaceutical development, quality assurance, and regulatory requirements
	Welcome
		Objectives of the meeting
		Expected outcomes
		Presentations on TB FDC issues
		Presentations and discussions on malaria FDC issues
		Presentations and discussions concerning ARV FDCs
		Presentation and discussion of cross-cutting issues related to logistics, adherence and resistance with FDCs
		Procurement experiences
		Intellectual property and industry issues
		Regulatory issues
		Concluding session
	Fixed-dose combinations for tuberculosis: lessons learned from a clinical, formulation and regulatory perspective
		Abstract
		Tuberculosis in the world of today
		Combination therapy and fixed-dose combination (FDC) formulations in the management of TB
		Registration requirements for rifampicin-containing FDC formulations
		Conclusions
		Acknowledgments
		Annex: Bioavailability of rifampicin, the Biopharmaceutic Classification System and the 4D approach to disease management
		Results/c results/comments
		References
	Product costs of fixed-dose combination tablets in comparison with separate dispensing and or co-blistering of antituberculosis drugs
		Introduction
		Method
		Results
		Discussion
		References
	Fixed-dose combinations: artemisinin-based combination therapies for malaria treatment
		Introduction
		Background
		Implementation issues
		Process leading to the development of guidelines on the use of artemisinin-based combination therapies (ACTs)
		Support to countries in the implementation of ACTs
		Challenges/way forward
		Recommendations for further research
		Conclusion
		References
	Developing combinations of drugs for malaria examination of critical issues and lessons learnt
		Background
		Parasite resistance to antimalarial drugs: a major impediment to effective control
		Strategies to overcome resistance
		Evidence - the key to sensible recommendations
		Further work on the artemisinins
		Recommendations & outstanding challenges
		References
	Safety and long-term effectiveness of generic fixed-dose formulations of nevirapine-based HAART amongst antiretroviral-naïve HIV-infected patients in India
		Abstract
		Introduction
		Methods
		Results
		Discussion
		Immunological improvement
		Viral load
		Clinical findings
		Conclusions
		References
	Effect of introduction of fixed-dose combinations on the drug supply chain: experiences from the field
		Abstract
		Introduction
		Procurement
		Distribution
		Prescribing
		Dispensing to patients
		Cost to patient
		Patient use
		Consumption data
		Conclusion
		References
	Effect of fixed-dose combination (FDC) medications on adherence and treatment outcomes
		Introduction
		Evidence of effect of FDCs or unit-of-use packaging on adherence and treatment outcomes
		Research needs
		Conclusion
		Acknowledgements
		References
	Effect of fixed-dose combination (FDC) drugs on development of clinical antimicrobial resistance: a review paper
		Executive summary
		Introduction
		Biological basis for drug resistance to anti-TB, HIV/AIDS and malaria drugs
		Combination drugs in the context of AMR
		Overcoming clinical resistance using combinations: what is the evidenceⁱ?
		Future research needs
		Conclusion
		Selected studies comparing combinations, FDCs, blister packs and monotherapy with regard to development of antimicrobial resistance
		References
	Fixed-dose combination (FDC) drugs availability and use as a global public health necessity: intellectual property and other legal issues
		Executive summary
		Introduction
		IPRs and Fixed-dose Combinations: Introduction to the “Anticommons Problem”
		IPRs and Fixed-dose Combinations: The “Anticommons Problem” (II)
		Overcoming IP/Legal barriers
		Back to the Future: TRIPS, Public Health, Access to Medicines
		Recommendations
		Conclusions
		References
	Pharmaceutical development and quality assurance of FDCs
		Abstract
		Introduction
		Preformulation studies
		Some examples of the relevance of the properties of the API to product formulation!
		Good Manufacturing Practice (GMP)
		Issues that may arise in the formulation of FDCs that do not arise for single entity products include:
		Changes to registered products (variations)
		Quality control of FDCs
		Recommendations
		References
	Annotated agenda
	List of participants

References

1. Benner J, Glynn R, Mogun H, Neumann P, Weinstein M, Avorn J. Long-term persistence in use of statin therapy in elderley patients. JAMA 2002;288:455-61.

2. Morrison A, Wertheimer A, Berger M. Interventions to improve antihypertensive drug adherence: A quantitative review of trials. Formulary 2000;35:234-55.

3. World Health Organisation. Adherence to long-term therapies. Evidence for Action. Geneva: WHO, 2003.

4. McDonald H, Garg A, Haynes R. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002;288:2868-79.

5. Maggiolo F, Ripimonti D, Arici C, Gregis G, Quinzan G, Camacho G, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clinical Trials 2002;3:371-8.

6. Murray M, Birt J, Manatunga A, JC D. Medication compliance in elderly outpatients using twice daily dosing and unit-of-use packaging. Ann Pharmacother 1993;27(616-21).

7. Paes A, Bakker A, Soe-Agnie C. Impact of dosage frequency on patient compliance. Diabetes Care 1997;20:1512-17.

8. World Health Organisation. Scaling up antiretroviral therapy in resource-limited settingns: treatment guidelines for a public health approach. Geneva: WHO, 2003.

9. Silveira Vl, Pinheiro CAT, Drachler ML, Leite JCC. Adherence to antiretroviral therapy and characteristics of treatment regimens among HIV-infected patients. (abstract) 2nd IAS Conference on HIV pathogenesis and treatment; 2003; Paris.

10. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Under review at BWHO 2003.

11. Su W, Perng R. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tuberc Lung Dis 2002;6:1029-32.

12. Geiter L, O'Brien R, Combs D, Snider D. United States Public Health Service Tuberculosis Therapy Trial 21: Preliminary results of an evaluation of a combination tablet of isoniazid, rifampicin and pyrazinamide. Tubercle 1987;68:41-6.

13. Eron J, Yetzer E, Ruane P, Becker S, Sawyerr G, Fisher R, et al. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS 2000;14:671-81.

14. Revankar C, Nivedita G, Sorensen B, Naik S. Further observations on MDT blister-calendar packs in vertical leprosy eradication programmes a -multicentre study (Phase II). Lepr Rev 1993;64:250-4.

15. Yeboah-Antwi K, Gyapong J, Asare I, Barnish G, Evans D, Adjei S. Impact of prepackaging antimalarial drugs on cost to patients and compliance with treatment. Bulletin of the World Health Organisation 2001;79:394-9.

16. Simmons D, Upjohn M, Gamble G. Can medication packaging improve glycemic control and blood pressure in type 2 diabetes? Results from a randomized controlled trial. Diabetes Care 2000;23(2):153-6.

17. Binstock M, Franklin K. A comparison of compliance techniques on the control of high blood pressure. AJH 1988;1:192S-194S.

18. Becker L, Glanz K, Sobel E, Mossey J, Zinn S, Andrews Knott K. A randomized trial of special packaging of antihypertensive medications. J Fam Pract 1986;22:357-361.

19. Rehder T, McCoy L, Blackwell B, Whitehead W, Robinson A. Improving medication compliance by counseling and special prescription container. Am J Hosp Pharm 1980;37(379-85).

20. Ware G, Holford N, Davison J. Unit dose dispensing. NZ Med J 1991;104:495-7.

21. Wong B, Norman D. Evaluation of a novel medication aid, the calendar blister-pak, and its effect on drug compliance in a geriatric outpatient clinic. J Am Geriatric Soc 1987;35:21-26.

22. Crome P, Akehurst M, Keet J. Drug compliance in elderly hospital in-patients: Trial of the Dosett box. The Practitioner 1980;224:782-5.

23. Crome P, Curl B, Boswell M, Corless D, Lewis R. Assessment of a new calendar pack the - C - Pak. Age Ageing 1982;11:275-9.

24. Haynes R, McKibbon K, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996;348:383-6.

25. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampicin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 1991;143:707-12.

26. Teo S. Assessment of a combined preparation of isoniazid, rifampicin, and pyrazinamide (Ritafer) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. Int J Tuberc Lung Dis 1999;3:126-32.

27. Hong Kong Chest Service/British Medical Research Council. Acceptability, compliance, and adverse reactions when isoniazid, rifampicin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. Am Rev Respir Dis 1989;140:1618-22.

28. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 montyhs of pyrazinamide in pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide. Am Rev Respir Dis 1991;143:700-6.

29. Zhang L. Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis. Current Therapeutic Research 1996;57:849-856.

30. Qingjun L, Jihui D, Laiyi T, Xiangjun Z, Jun L, Hay A, et al. The effect of drug packaging on patients compliance with treatment for plasmodium vivax malaria in China. Bulletin of the World Health Organisation 1998;76(Suppl 1):21-7.

31. Shwe T, Lwin M, Aung S. Influence of blister packaging on the efficacy of artesunate and mefloquine over artesunate alone in community-based treatment of non-severe falciparum malaria in Myanmar. Bulletin of the World Health Organisation 1998;76(Suppl 1):35-41.

32. Ibarra I, Martinez-Bengoechea MJ, Peral J, Santos A, Illaro A, Lertxundi U et al. Assessing adherence in a treatment simplification. (abstract) 2nd IAS Conference on HIV pathogenesis and treatment; 2003; Paris.

33. Barigye H, Luyirika E. The challenges of paediatric ARV formulations in resource-poor countries the - Ugandan experience. (abstract) 2nd IAS Conference on HIV pathogenesis and treatment; 2003; Paris.

34. Rozenbaum W, Chauveau E. Phase 3 study of the antiviral activity of AZT + 3TC given as separate regimens versus a new fixed-dose combination (abstract 669). The 5th Conference on Retroviruses and Opportunistic Infections; 1998; Chicago.